Skip to content

Ketamine research published in 2022

Page 12 of 14: studies 221 to 240 of 261, newest first. Back to the ketamine overview

Studies

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial

British medical journal February 2, 2022 M. Abbar, C. Demattei, Wissam El-Hage et al. 172 citations

Abstract Objective To confirm the rapid onset anti-suicidal benefits of ketamine in the short term and at six weeks, overall and according to diagnostic group. Design Prospective, double blind, superiority, randomised placebo controlled trial. Setting Seven French teaching hospitals between 13 April 2015 and 12 March 2019. Eligibility criteria for participants Aged 18 or older with current...

The Effectiveness of Repeated Intravenous Ketamine on Subjective and Objective Psychosocial Function in Patients with Treatment-Resistant Depression and Suicidal Ideation.

Journal of Affective Disorders February 1, 2022 Yanling Zhou, Chengyu Wang, Xiaofeng Lan et al.

BACKGROUND Ketamine has rapid and robust antidepressant effects in adults with treatment-resistant depression (TRD), while its effects on functional outcomes have not been sufficiently evaluated. The aim was to evaluate the efficacy of ketamine treatment on both subjective and objective functioning, and to explore whether improvements in depressive symptom and cognition mediated changes in...

Is (R)-ketamine a Potential Therapeutic Agent for Treatment-Resistant Depression with Less Detrimental Side Effects? A Review of Molecular Mechanisms Underlying Ketamine and its Enantiomers.

Biochemical Pharmacology February 1, 2022 Ellen Scotton, Bárbara Antqueviezc, Mailton Vasconcelos et al. 35 citations

Approximately one-third of individuals with major depressive disorder are resistant to conventional antidepressants (i.e., monoamine-based therapies), and, even among respondents, a proper therapeutic effect may require weeks of treatment. Ketamine, a racemic mixture of the two enantiomers, (R)-ketamine and (S)-ketamine, is an N-methyl-d-aspartate receptor (NMDAR) antagonist and has been shown...

Hallucinogen Use and Misuse in Older Adults.

Clinics in geriatric medicine February 1, 2022 Wm Maurice Redden, Saif-Ur-Rahman Paracha, Quratulanne Sheheryar 7 citations

Hallucinogens, or psychedelics, are substances/drugs that have been used for over a millennium. The most well known are LSD, psilocybin, mescaline, and PCP. These substances may induce hallucinations as well as cause somatic and psychological symptoms. Because of the Controlled Substances Act of 1970, there has been very little research done to determine the long-term consequences or perhaps...

Rewarding and reinforcing effects of two dissociative-based new psychoactive substances, deschloroketamine and diphenidine, in mice.

Pharmacology, Biochemistry, and Behavior February 1, 2022 Jin Mook Kim, Boreum Han, Hyun Kyu Min et al. 4 citations

Dissociative-based new psychoactive substances (NPSs) are increasingly available through the Internet, and public health problems related to the recreational use of these substances have been increasing globally. Two such NPSs are deschloroketamine and diphenidine, which are primarily used recreationally as ketamine substitutes. However, there is little scientific evidence to describe the...

DOI: 10.1016/j.pbb.2022.173333 (opens in new tab) Full text (opens in new tab) Conditioned place preference Dependence liability Deschloroketamine Diphenidine +2

Impaired glutamate reuptake induces synaptic mistuning in rat hippocampal slices, that can be counteracted by ketamine

bioRxiv Preprint Server January 25, 2022 Erika Vazquez Juarez, Ipsit Srivastava, Maria Lindskog 1 citation preprint

Mistuning of synaptic transmission has been proposed to underlie many psychiatric disorders, with decreased reuptake of the excitatory neurotransmitter glutamate as one contributing factor. Synaptic tuning occurs through several diverging and converging forms of plasticity. By recording evoked field postsynaptic potentials in the CA1 area in hippocampal slices, we found that inhibiting...

Combined Administration of (R)-Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Induces Rapid and Sustained Effects in the CUMS Model of Depression via a TrkB/BDNF-Dependent Mechanism

Pharmaceuticals January 21, 2022 Anna Rafało-Ulińska, P. Brański, Agnieszka Pałucha-Poniewiera

Ketamine is an effective, rapid-acting antidepressant drug (RAAD), but it induces side effects. To overcome these challenges, attempts have been made to use safer enantiomer ((R)-ketamine) or mGlu2/3 receptor antagonists, which induce ketamine-like effects and enhance its action. Here, we propose combining these two strategies to investigate the antidepressant-like effects of low doses of two...

Ketamine acutely impairs memory consolidation and repeated exposure promotes stereotyped behavior without changing anxiety- and aggression-like parameters in adult zebrafish.

Physiology & Behavior January 18, 2022 Paula Michelotti, Francini Franscescon, T. E. Müller et al.

Ketamine is a dissociative anesthetic in human and veterinary clinic, as well as an abuse drug that acts on several neurotransmitter systems. The use of alternative animal models, such as zebrafish, is emerging to study the effects of drugs on neurobehavioral responses. Here, we evaluated the effects of ketamine on memory consolidation (acute protocol), as well as on anxiety-, aggressive-like...

Ketamine for the treatment of mental health and substance use disorders: comprehensive systematic review - CORRIGENDUM.

BJPsych Open January 18, 2022 Zach Walsh, Özden Merve Mollaahmetoğlu, Joseph M. Rootman et al. 28 citations

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

DOI: 10.1192/bjo.2022.5 (opens in new tab) Full text (opens in new tab) Ketamine therapy Ketamine treatment Ketamine application Ketamine use +12

Neuroprotective effect of hesperidin and its combination with coenzyme Q10 on an animal model of ketamine-induced psychosis: behavioral changes, mitochondrial dysfunctions, and oxidative stress

Future Journal of Pharmaceutical Sciences January 15, 2022 Naresh Kumar, M. Yadav, Ashok Kumar et al.

Psychosis is a complex mental illness divided by positive symptoms, negative symptoms, and cognitive decline. Clinically available medicines are associated with some serious side effects which limit their use. Treatment with flavonoids has been associated with delayed onset and development, decreased risk, or increased improvement of various neuropsychiatric disorders including psychosis with...

Relationship Between Dissociation and Antidepressant Effects of Esketamine Nasal Spray in Patients With Treatment-Resistant Depression

The International Journal of Neuropsychopharmacology January 12, 2022 Guang Chen, Li Chen, Yun Zhang et al.

Abstract Background In this post-hoc analysis, data from 2 positive, pivotal, phase 3 trials of esketamine nasal spray (ESK) in treatment-resistant depression (TRD)—short-term study (TRANSFORM-2) and maintenance study (SUSTAIN-1)—were analyzed to evaluate the relationship between dissociation and antidepressant effects of ESK. Methods Analysis by responder status, correlation analysis, and...

Acute effects of ketamine on the pregenual anterior cingulate: linking spontaneous activation, functional connectivity, and glutamate metabolism

European Archives of Psychiatry and Clinical Neuroscience January 12, 2022 Matti Gärtner, Anne Weigand, Milan Scheidegger et al. 13 citations

Abstract Ketamine exerts its rapid antidepressant effects via modulation of the glutamatergic system. While numerous imaging studies have investigated the effects of ketamine on a functional macroscopic brain level, it remains unclear how altered glutamate metabolism and changes in brain function are linked. To shed light on this topic we here conducted a multimodal imaging study in healthy...

DOI: 10.1007/s00406-021-01377-2 (opens in new tab) Full text (opens in new tab) Ketamine Anterior cingulate cortex Glutamine Glutamate receptor +5

A Cohort-Based Case Report: The Impact of Ketamine-Assisted Therapy Embedded in a Community of Practice Framework for Healthcare Providers With PTSD and Depression

Frontiers in Psychiatry January 12, 2022 Shannon Dames, Pamela Kryskow, Crosbie Watler 38 citations

Amid an international pandemic and a worsening mental health crisis, ketamine-assisted therapy is emerging as a promising solution for those deemed “treatment resistant.” Post-traumatic stress disorder (PTSD) and depression are on the rise, with accelerating direct (e.g., burden of suffering) and indirect (e.g., disability/role impairment and impact on family) costs. Psychedelic-assisted...

Adjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder

American Journal of Psychiatry January 11, 2022 Meryem Grabski, Amy Mcandrew, Will Lawn et al. 169 citations

OBJECTIVE: Early evidence suggests that ketamine may be an effective treatment to sustain abstinence from alcohol. The authors investigated the safety and efficacy of ketamine compared with placebo in increasing abstinence in patients with alcohol use disorder. An additional aim was to pilot ketamine combined with mindfulness-based relapse prevention therapy compared with ketamine and alcohol...

Whole blood transcriptional signatures associated with rapid antidepressant response to ketamine in patients with treatment resistant depression

Translational Psychiatry January 10, 2022 F. Cathomas, L. Bevilacqua, Aarthi Ramakrishnan et al. 44 citations

Ketamine has rapid and sustained antidepressant effects in patients with treatment-resistant depression (TRD). However, the underlying mechanisms of action are not well understood. There is increasing evidence that TRD is associated with a pro-inflammatory state and that ketamine may inhibit inflammatory processes. We thus investigated whole blood transcriptional profiles related to TRD and...

Guanosine boosts the fast, but not sustained, antidepressant-like and pro-synaptogenic effects of ketamine by stimulating mTORC1-driven signaling pathway.

European Neuropsychopharmacology January 7, 2022 A. Camargo, A. P. Dalmagro, Eslen Delanogare et al.

The mTORC1-dependent dendritic spines formation represents a key mechanism for fast and long-lasting antidepressant responses, but it remains to be determined whether this mechanism may account for the ability of guanosine in potentiating ketamine's actions. Here, we investigated the ability of ketamine plus guanosine to elicit fast and sustained antidepressant-like and pro-synaptogenic effects...

Dynamic reconfiguration of frequency-specific cortical coactivation patterns during psychedelic and anesthetized states induced by ketamine

Neuroimage January 7, 2022 Duan Li, Phillip E. Vlisides, George A. Mashour 24 citations

Recent neuroimaging studies have demonstrated that spontaneous brain activity exhibits rich spatiotemporal structure that can be characterized as the exploration of a repertoire of spatially distributed patterns that recur over time. The repertoire of brain states may reflect the capacity for consciousness, since general anesthetics suppress and psychedelic drugs enhance such dynamics. However,...

DOI: 10.1016/j.neuroimage.2022.118891 (opens in new tab) Ketamine Wakefulness Consciousness Repertoire +1

Increase in thalamic cerebral blood flow is associated with antidepressant effects of ketamine in major depressive disorder

The World Journal of Biological Psychiatry January 5, 2022 Matti Gärtner, Mischa de Rover, Lena Václavů et al. 11 citations

Ketamine is a promising treatment option for patients with Major Depressive Disorder (MDD) and has become an important research tool to investigate antidepressant mechanisms of action. However, imaging studies attempting to characterise ketamine's mechanism of action using blood oxygen level-dependent signal (BOLD) imaging have yielded inconsistent results- at least partly due to intrinsic...

Prophylactic efficacy of ketamine, but not the low-trapping NMDA receptor antagonist AZD6765, against stress-induced maladaptive behavior and 4E-BP1-related synaptic protein synthesis impairment.

Progress in Neuro-Psychopharmacology and Biological Psychiatry 2022 A. Camargo, A. C. N. Torrá, A. P. Dalmagro et al.

Ketamine enhances the resilience against stress-induced depressive-like behavior, but its prophylactic efficacy in anxiety-related behaviors remains to be elucidated. Moreover, there is a need for developing novel preventive strategies against depressive- and anxiety-like behavior. AZD6765, a low-trapping NMDA receptor antagonist, shares with ketamine common molecular targets and produces...

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders: a case report.

EXCLI journal 2022 Miriam Olivola, Vincenzo Arienti, Nicola Bassetti et al.

Major depression is a common comorbidity in autism spectrum disorder (ASD), often difficult to identify and to treat. Autistic subjects are more at risk for suicidal thoughts and behaviors compared to typically developing peers. Unfortunately, ASD individuals are more frequently treatment-resistant and often show side-effects which reduce efficacy. Intranasal esketamine has been recently...